Details of the Drug Combination

General Information of Drug Combination (ID: DCJ5U2X)

• Drug Combination Name: Carglumic acid + Metyrosine
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Carglumic acid (DMCY0TI): Small molecular drug
  Metyrosine (DMBYCU0): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 13.13
  Bliss Independence Score: 13.13
  Loewe Additivity Score: 15.89
  LHighest Single Agent (HSA) Score: 15.89

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Carglumic acid

Disease Entry	ICD 11	Status	REF
Acute hyperammonaemia	5C50.A	Approved	[2]

Carglumic acid Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Carbamoyl-phosphate synthetase I (CPS1)	TT42M75	CPSM_HUMAN	Activator	[4]

Indication(s) of Metyrosine

Disease Entry	ICD 11	Status	REF
Pheochromocytoma	5A75	Approved	[3]

Metyrosine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tyrosine 3-monooxygenase (TH)	TTUHP71	TY3H_HUMAN	Binder	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7458).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6956).
• [4] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [5] Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.